Genelux (GNLX) Stock Price, News & Analysis

Company Overview

Genelux Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for cancer. The company’s research centers on oncolytic immunotherapies, which are designed to selectively infect and destroy tumor cells while stimulating the body’s immune response against cancer.

Genelux’s lead investigational product is olvimulogene nanivacirepvec, also known as Olvi-Vec or GL-ONC1. Olvi-Vec is a modified vaccinia virus being evaluated in clinical studies for several solid tumors, including ovarian cancer and other advanced or recurrent cancers. The company’s development programs have also included studies involving lung cancer and other tumor types.

The company uses its proprietary Voyager-V1 platform to identify and develop oncolytic viruses with potential anticancer activity. Genelux is headquartered in Westlake Village, California, and its programs are primarily directed toward clinical development in the United States and other markets where clinical studies may be conducted. Its products remain investigational and are subject to clinical and regulatory review.

Key Stats

• Today's Range: $2.50 to $2.57
• 50-Day Range: $2.34 to $3.05
• 52-Week Range: $2.29 to $8.53
• Volume: 143,116 shs
• Average Volume: 320,079 shs
• Market Capitalization: $114.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Genelux Stock Analysis - MarketRank™

Genelux scored higher than 37% of companies evaluated by MarketBeat, and ranked 585th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genelux has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Genelux has a consensus price target of $18.00, representing about 611.5% upside from its current price of $2.53.

Amount of Analyst Coverage

Genelux has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Genelux are expected to grow in the coming year, from ($0.81) to ($0.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genelux is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genelux is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Genelux has a P/B Ratio of 8.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.02% of the float of Genelux has been sold short.

Short Interest Ratio / Days to Cover

Genelux has a short interest ratio ("days to cover") of 10.65, which indicates bearish sentiment.

Change versus previous month

Short interest in Genelux has recently increased by 7.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genelux does not currently pay a dividend.

Dividend Growth

Genelux does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Genelux this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for GNLX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,402.00 in company stock.

Percentage Held by Insiders

7.50% of the stock of Genelux is held by insiders.

Percentage Held by Institutions

37.33% of the stock of Genelux is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GNLX
• CIK: 1231457
• Web: www.genelux.com
• Phone: 805-267-9889
• Fax: N/A
• Employees: 26
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Genelux: $18.00
• High Price Target: $20.00
• Low Price Target: $16.00
• Potential Upside/Downside: +611.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.15 million
• Net Margins: N/A
• Pretax Margin: -444,950.00%
• Return on Equity: -205.85%
• Return on Assets: -138.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.39

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 11,445.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 8.43

Miscellaneous

• Outstanding Shares: 45,240,000
• Free Float: 41,852,000
• Market Cap: $114.46 million
• Optionable: Not Optionable
• Beta: 0.57